U.S. Markets close in 1 hr 41 mins

Ligand Pharmaceuticals Incorporated (LGND)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
135.69+0.54 (+0.40%)
As of 2:19PM EDT. Market open.
People also watch
NBIXINCYVICLALKSMDCO
  • l
    longvrts
    longvrts

    LGND partner Alder announces positive PII results in Dry Eye Disease indication:

    http://ir.aldeyra.com/releasedetail.cfm?ReleaseID=1040023

    Aldeyra Therapeutics Announces Positive Results from Dry Eye Disease Phase 2a Clinical Trial
    /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:
    ir.aldeyra.com
  • l
    longvrts
    longvrts

    LGND OmniAb partner HanAll signs licensing agreement for biologics in China:

    http://www.asiaone.com/business/hanall-biopharma-and-harbour-biomed-sign-collaboration-and-license-agreement-to-develop-two

    HanAll Biopharma and Harbour BioMed Sign Collaboration and License Agreement to Develop Two Novel Biologic Therapies in Greater China
    AsiaOne - . Read more at AsiaOne
    www.asiaone.com
  • A
    Abigail
    Abigail

    The last time LGND did something like this it blew up. Not sure how https://activepennystocks1.blogspot.com finds all these incredible trade ideas but im happy.

    Penny Stock
    activepennystocks1.blogspot.com
  • m
    martyboy17
    martyboy17
    after 10 years, I sold my 316 shares at 7.50. GREAT COMPANY, I will continue to watch it and the fundamentals, could very well be back in with a 20% pullback, if, that should occur. Good luck all.
  • F
    FACTSMAN123
    FACTSMAN123
    I have high positive expectations for news coming at the Ligand presentation tomorrow afternoon.
  • F
    FACTSMAN123
    FACTSMAN123
    If Viking continues to improve its market cap, doesn't it seem logical that Ligand will revise its holdings in
    a positive way? I say this because they previously wrote off a significant amount of their investment. (I don't
    believe this will have a significant impact, but I believe in consistency.)
  • B
    BlockbusterPicks
    BlockbusterPicks

    SLNO (MC $26 M) BLOCKBUSTER in Phase 3 /Rare Disease +Orphan Status /$2+ BILLION Market /NO Debt = REAL Unknown low float stock with 1000% upside Potential and more .Next billion dollar rare disease company like SRPT here .GLTA

    Soleno therapeutics (SLNO)

    Market Cap $26 Million
    Cash: $8 Million
    Price $0.54

    Shares Out: 47.6 Million ( 36 Million shares held by Insiders & Institutions)

    Initiating Coverage June 26, 2017
    http://www.lifescicapital.com/wp-content/uploads/Soleno.pdf

    •Company expects to initiate pivotal Phase III clinical trial by year-end 2017; will take approximately 9-12 months to complete

    Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program at the end of 2017.

    Market Opportunity for PWS is Substantial.

    While the lack of approved treatments for PWS alone make it difficult to assess the market, sales of Pfizer’s (NYSE: PFE)
    Genotrop in (somatropin) can provide some insight despite being indicate for PWS, in addition to, growth failure due to growth hormone deficiency(GHD),Turner syndrome,idiopathic short stature,and small for gestational age.This product achieved its highest revenue in 2008,with worldwide sales of approximately $900 million.While somatropin has been proven to improve growth and body composition, it does not affect the key disease component of hyperphagia and use is associated with substantial risk. Soleno is developing DCCR for the treatment of PWS,to help address the unmet need of this patient population. To assess the potential of DCCR for PWS, we performed a scenario analysis, which indicates that annual sales could be in the range of $1.1 billion given a moderate price point and 50% market penetrance.

  • l
    longvrts
    longvrts
    LGD-6972 PII data:

    1. Robust safety and efficacy with clinically meaningful decrease in A1C, good dose response in the range of 5-15 mg, and excellent tolerability/safety profile.
    2. GRA mechanism targeted by LGD-6972 is active both in Type 1 and Type 2 diabetes, opening up a substantial market for this diabetes drug.
    3. LGND will get a solid partnership for LGD-6972 if it decides to partner after this PII, but still has the option to run the PIII on its own and then partner on favorable terms such as 50/50 split of revenues.

    LDG-6972 will make a significant contribution to the growth of LGND market cap going forward.
  • l
    longvrts
    longvrts

    LGND partner AMGN claims Kyprolis should be standard of care for multiple myeloma:

    https://www.thepharmaletter.com/article/data-shows-kyprolis-should-be-standard-of-care-claims-amgen

    Data shows Kyprolis should be ‘standard of care’, claims Amgen
    The US Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) based on data demonstrating that Kyprolis (carfilzo
    www.thepharmaletter.com
  • P
    Pete
    Pete
    A 1% decrease in A1C is clinically significant and that P value is very convincing. In my cursory review of clinical results for SGLT2 inhibitor INVOKANA, this impact on A1C is comparable to that blockbuster drug, depending on the starting A1C level.

    We don't know the relative variation in response and whether the impact is more or less in different sub-populations...yet.

    SGLT inhibition is a different mechanism with a different profile of health benefits and risks.

    They state they will pursue this for Type I and Type II diabetes...no approved drugs for Type I diabetics. Look for partnering announcements soon and short interest to vaporize.
  • m
    martyboy17
    martyboy17
    We just got amazing news on Diabetes. Next VKTX, buy that now, it will be 5.00 in a hurry in 4th quarter. Disclosure, I have 25,000 shares of VKTX at 1.14 average.
  • L
    Linda
    Linda
    Sage Therapeutics' stock sinks after disappointing late-stage trial of SRSE treatment
  • A
    Anna
    Anna
    LGND looks decent today but latley it has been like watching paint dry. For some decent trade tips check out thestock-dork now .
  • m
    martyboy17
    martyboy17
    Why don't we hear from Duche bank, you know, the ones who called 110, and we watched it drop lower than than. I bet ya dollars to donuts, that Duche band bot a crud load of shares after the downgrade, they just reached into Grannies purse and stole, not me.
  • b
    biomaven
    biomaven

    LGND partner ImmunoPrecise announces successful development of fully human Ab's using OmniAb platform:

    https://immunoprecise.com/immunoprecise-announces-rd-success-using-omniab-platform-develop-fully-human-antibodies/

    ImmunoPrecise Announces R&D Success Using The OmniAB® Platform to Develop Fully Human Antibodies - ImmunoPrecise Antibodies LTD
    Victoria, British Columbia, Canada, August 29, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE:[...]
    immunoprecise.com
  • m
    martyboy17
    martyboy17
    MARK MY WORDS, I HAVE OWNED THIS SINCE THE REVERSE SPLINT AT 7.50. AMAZING RUN, AMAZING COMPANY, AMAZING MANAGEMENT. THIS PUPPY, AGAIN, MARK MY WORDS, AS STILL SOMEWHAT UNAPPRECATED AND UNDISCOVED AND MISUNDERSTOOD, WILL BE 250 NEXT YEAR WHEN MORE INVESTORS APPRECIATE THIS MAGNIFICENT STORY.
  • l
    longvrts
    longvrts

    LGND partner ARMO BioSciences raises $67 to develop OmniAb based IO therapeutics:

    http://www.prnewswire.com/news-releases/armo-biosciences-raises-67-million-in-a-series-c-1-financing-300510640.html

    ARMO BioSciences Raises $67 Million in a Series C-1 Financing
    REDWOOD CITY, Calif., Aug. 29, 2017 /PRNewswire/ -- ARMO BioSciences, Inc., a late-stage immuno-oncology company,...
    www.prnewswire.com
  • F
    FACTSMAN123
    FACTSMAN123
    Diabetes 2 drug should be worth a lot of money by Ligand standards. Any thoughts on when the deal will be
    done?
  • m
    martyboy17
    martyboy17
    weak as can be, some new won't even help, when wall street decides to poop on you, it poop's on you... Damn thing will be 140 by end of the year, the banks want in and are driving down, way institutonally held..